Marc-Antoine Belaud-Rotureau

Marc-Antoine Belaud-Rotureau

Auto-generated profile, based on publicly available information

Marc-Antoine Belaud-Rotureau

Service de Cytogénétique et Biologie Cellulaire, CHU de Rennes, 35000 Rennes, France; Université de Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de Recherche en santé, environnement et travail) - UMR_S1085, 35000 Rennes, France

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2014 in Human Pathology
Verified
Journal Article
Closed access
JDJulien Dagher
Julien Dagher
FDFrédéric Dugay
Frédéric Dugay
NRNathalie Rioux-Leclercq
Nathalie Rioux-Leclercq
GVGregory Verhoest
Gregory Verhoest
EOEmmanuel Oger
Emmanuel Oger
MBMarc-Antoine Belaud-Rotureau
Marc-Antoine Belaud-Rotureau

1 October 2019 in Human Pathology
Verified
Journal Article
Closed access
MBMarion Beaumont
Marion Beaumont
FDFrédéric Dugay
Frédéric Dugay
SKSolène-Florence Kammerer-Jacquet
Solène-Florence Kammerer-Jacquet
SJSylvie Jaillard
Sylvie Jaillard
FCFlorian Cabillic
Florian Cabillic
MBMarc-Antoine Belaud-Rotureau
Marc-Antoine Belaud-Rotureau

20 May 2016 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
Solene-Florence Kammerer-JacquetSolene-Florence Kammerer-Jacquet
Solene-Florence Kammerer-Jacquet
SMSarah Medane
Sarah Medane
ABAngelique Brunot
Angelique Brunot
BPBenoit Peyronnet
Benoit Peyronnet
RMRomain Mathieu
Romain Mathieu
NRNathalie Rioux-Leclercq
Nathalie Rioux-Leclercq
E16079 Background: Clear cell renal cell carcinoma (ccRCC) are highly metastatic tumors. Anti-vascular growth epithelial factor (VEGF) therapies are currently used in first line of metastatic ccRCC but most patients develop resistance to these treatments. Cabozantinib, an inhibitor of tyrosine kinases including VEGFR, MET and AXL recently shows interesting results in second line treatment. Moreover, the HGF/MET signaling pathway implicated in angiogenesis may be responsible for resistance to anti-VEGF therapy. To better understand MET role in metastatic ccRCC and potential resistance, we assessed MET complete status in a well-characterized population of 90 patients with metastatic ccRCC treated by first line sunitinib therapy. Methods: For this purpose, we studied MET expression by immunohistochemistry (IHC), MET amplification by fluorescence in situ hybridization (FISH) on formalin-fixed paraffin-embeded (FFPE) samples and MET mutation by next generation sequencing (NGS) on frozen samples in their 90 primary tumors. MET status was then correlated to pathological criteria using Chi-squared test and clinical outcome using Kaplan Meier curves compared by log rank test. Results: 31.1% of ccRCCs had low expression of MET (absent to weak intensity by IHC) versus 68.9% with high expression (moderate to strong intensity). High expression of MET was associated with gain in FISH analyses (p = 0.0284) without amplification. No mutation was detected by NGS. High expression of MET was associated with lymph node invasion and sarcomatoid component (p = 0.004 and p = 0.029). No statistical differences were observed between the two groups of patients in terms of progression free survival and overall survival after sunitinib introduction (p = 0.72 and p = 0.93). Conclusions: This study is the first to analyze complete MET status in metastatic ccRCC treated by sunitinib. High expression of MET, although not associated with sunitinib resistance, may suggest a benefit from MET inhibitors.

1 September 2016 in Morphologie
Verified
Journal Article
Closed access
CLClaire Lamaison
Claire Lamaison
LCLaurence Cornevin
Laurence Cornevin
AKAnthony Kergal
Anthony Kergal
STSaloua Toujani
Saloua Toujani
MBMarion Beaumont
Marion Beaumont
CHCatherine Henry
Catherine Henry

1 March 2014 in Morphologie
Verified
Journal Article
Closed access
FDF. Dugay
F. Dugay
JDJ. Dagher
J. Dagher
GVG. Verhoest
G. Verhoest
CHC. Henry
C. Henry
SJS. Jaillard
S. Jaillard
MBM.-A. Belaud-Rotureau
M.-A. Belaud-Rotureau

1 December 2017 in Morphologie
Verified
Journal Article
Closed access
MBMarion Beaumont
Marion Beaumont
PLPhilippe Loget
Philippe Loget
ELErika Launay
Erika Launay
MGMarjorie Gournay
Marjorie Gournay
CQChloé Quelin
Chloé Quelin
SJSylvie Jaillard
Sylvie Jaillard